Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Breaking & Recent News Onconetix Inc ONCO

Healthcare Biotechnology
Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men’s health and oncology in the United States, the European Union, and Non-European Union. The company offers Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. It has a license agreement with LabCorp to develop and commercialize Proclarix and... see more

Recent & Breaking News (NDAQ:ONCO)

Onconetix Reports Q1 2026 Progress at Proteomedix AG, Including Two New Peer-Reviewed Publications and Initiation of U.S. Validation Study

GlobeNewswire 3 days ago

Onconetix Highlights Realbotix's Launch of Vinci AI Vision System with Delivery of First Vinci-Equipped Humanoid Robot to Ericsson

GlobeNewswire April 9, 2026

Onconetix Highlights Realbotix AI Humanoid Robot Delivery Update

GlobeNewswire April 2, 2026

Onconetix Appoints David White as Chief Executive Officer and Sammy Dorf as Member of the Board of Directors

GlobeNewswire March 31, 2026

Onconetix Highlights Realbotix's Role in Ericsson's World-First 6G Trial Demonstration

GlobeNewswire March 25, 2026

Onconetix, Inc. Announces 1-for-5 Reverse Stock Split

GlobeNewswire March 23, 2026

Onconetix to Acquire Realbotix LLC, USA-based, AI-Powered Humanoid Robotics Company

GlobeNewswire February 12, 2026

Onconetix Announces Financing Through a $12.9 Million Private Placement of Series D Preferred Stock and Warrants, Termination of Merger Agreement with Ocuvex, Inc. and Settlement of $8.8 Million Debt with Veru, Inc.

GlobeNewswire September 26, 2025

Joint Press Release: Onconetix and Ocuvex Announce Mutual Termination of Merger Agreement

GlobeNewswire September 26, 2025

Onconetix announces its subsidiary, Proteomedix, licenses manufacturing IP to Immunovia enabling them to independently produce key reagents for their pancreatic cancer test PancreaSureTM

GlobeNewswire September 22, 2025

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ONCO, WAT, XAGE on Behalf of Shareholders

PR Newswire July 18, 2025

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Onconetix, Inc. (NASDAQ: ONCO)

GlobeNewswire July 17, 2025

ONCO Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Onconetix, Inc. Is Fair to Shareholders

Business Wire July 16, 2025

Onconetix and Ocuvex Therapeutics announce execution of definitive merger agreement

GlobeNewswire July 16, 2025

Onconetix, Inc. Announces Positive Decision by Nasdaq Hearings Panel

GlobeNewswire June 16, 2025

Onconetix, Inc. Announces 1-for-85 Reverse Stock Split and Results of the Special Meeting of Stockholders

GlobeNewswire June 11, 2025

Onconetix, Inc. Announces Receipt of Additional Notice from Nasdaq

GlobeNewswire May 22, 2025

Onconetix, Inc. Announces Receipt of Additional Notice from Nasdaq

GlobeNewswire April 30, 2025

Onconetix Signs Letter of Intent for Potential Business Combination with Ocuvex Therapeutics, Inc.

GlobeNewswire April 8, 2025

Onconetix Announces Successful Clinical Validation of its Innovative Prostate Cancer Test Proclarix in a Danish cohort

GlobeNewswire March 24, 2025

Podcasts